Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): August 22, 2017
|
CORMEDIX
INC.
|
|
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
|
Delaware
|
001-34673
|
20-5894890
|
|
(State
or Other Jurisdictionof Incorporation)
|
(CommissionFile
Number)
|
(IRS
EmployerIdentification No.)
|
|
|
|
|
|
1430
U.S. Highway 206, Suite 200, Bedminster, NJ
|
07921
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (908) 517-9500
|
|
|
(Former
Name or Former Address, If Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Appointment
of Certain Officers; Compensatory Arrangements of Certain
Officers.
On
August 22, 2017, we and Judith Abrams, our Chief Medical Officer,
began discussing her resignation for personal reasons, which became
effective August 24, 2017. We do not owe Dr. Abrams any severance
obligations under her February 1, 2017 employment agreement, which
was included as an exhibit to our Current Report on Form 8-K filed
on February 1, 2017. In connection with her resignation, on August
25, 2017, we entered into a consulting agreement with Dr. Abrams
with a term of up to nine months. Pursuant to the consulting
agreement, Dr. Abrams will receive a monthly payment of
approximately $29,000, an upfront payment of approximately $17,000,
vesting in full of an option to purchase 46,250 shares of our
common stock granted under her employment agreement, and, at her
option, COBRA premiums for the period during which she receives
monthly payments under the consulting agreement.
The description of Dr. Abrams’s consulting agreement is
qualified in its entirety by reference to the full and complete
terms of the agreement, a copy of which will be filed as an
exhibit to the Form 10-Q for the quarter ending September 30,
2017.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
CORMEDIX
INC.
|
|
|
|
|
|
|
|
Date: August 28,
2017
|
By:
|
/s/
Robert
W. Cook
|
|
|
|
Name:
|
Robert W.
Cook
|
|
|
|
Title:
|
Chief Financial
Officer
|
|